{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:37:46Z","timestamp":1767832666179,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009960","name":"Pirkanmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["PSHP VTR 9X032"],"award-info":[{"award-number":["PSHP VTR 9X032"]}],"id":[{"id":"10.13039\/501100009960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.urolonc.2025.02.023","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:35:03Z","timestamp":1744270503000},"page":"398.e7-398.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Do differences in secondary treatment explain mortality impact of prostate cancer screening? \u2013 A randomized screening trial"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1817-0951","authenticated-orcid":false,"given":"Joona","family":"Lampela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Talala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L.J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Taari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Kujala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anssi P.","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-9590","authenticated-orcid":false,"given":"Teemu J.","family":"Murtola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2025.02.023_bib0001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.02.023_bib0002","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.02.023_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.eururo.2019.03.010","article-title":"Could differences in treatment between trial arms explain the reduction in prostate cancer mortality in the European randomized study of screening for prostate cancer?","volume":"75","author":"Carlsson","year":"2019","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.02.023_bib0004","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/ijc.24870","article-title":"The effect of study arm on prostate cancer treatment in the large screening trial ERSPC","volume":"126","author":"Wolters","year":"2010","journal-title":"Int J Cancer [Internet]"},{"key":"10.1016\/j.urolonc.2025.02.023_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canep.2016.11.005","article-title":"What explains the differences between centres in the European screening trial? A simulation study","volume":"46","author":"Nevalainen","year":"2017","journal-title":"Cancer Epidemiol"},{"issue":"17","key":"10.1016\/j.urolonc.2025.02.023_bib0006","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2010.09.033","article-title":"Change of tumour characteristics and treatment over time in both arms of the European randomized study of screening for prostate cancer","volume":"46","author":"Boevee","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.02.023_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2016.08.022","article-title":"Estimating bias in causes of death ascertainment in the Finnish Randomized Study of screening for prostate cancer","volume":"45","author":"Kilpel\u00e4inen","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.02.023_bib0008","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.eururo.2019.04.007","article-title":"The impact of design and performance in prostate-specific antigen screening: differences between ERSPC centers","volume":"76","author":"Heijnsdijk","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.02.023_bib0009","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2017.01.048","article-title":"Estimate of opportunistic prostate specific antigen testing in the Finnish randomized study of screening for prostate cancer","volume":"198","author":"Kilpel\u00e4inen","year":"2017","journal-title":"J Urol [Internet]"},{"issue":"5","key":"10.1016\/j.urolonc.2025.02.023_bib0010","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/JU.0000000000002835","article-title":"Prostate specific antigen and biopsy contamination in the G\u00f6teborg-1 randomized, population-based, Prostate cancer screening trial","volume":"208","author":"Kollberg","year":"2022","journal-title":"J Urol [Internet]"},{"issue":"10125","key":"10.1016\/j.urolonc.2025.02.023_bib0011","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.urolonc.2025.02.023_bib0012","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/aje\/kww084","article-title":"Prostate cancer and socioeconomic status in the Finnish randomized study of screening for prostate cancer","volume":"184","author":"Kilpel\u00e4inen","year":"2016","journal-title":"Am J Epidemiol [Internet]"},{"issue":"9","key":"10.1016\/j.urolonc.2025.02.023_bib0013","first-page":"939","article-title":"Prostate cancer incidence and survival in relation to education (United States)","volume":"15","author":"Steenland","year":"2004","journal-title":"Cancer Causes Contr"},{"issue":"2","key":"10.1016\/j.urolonc.2025.02.023_bib0014","first-page":"297","article-title":"A prospective study of socioeconomic status, prostate cancer screening and incidence among men at high risk for prostate cancer","volume":"24","author":"Rundle","year":"2013","journal-title":"Cancer Causes and Contr [Internet]"},{"issue":"3","key":"10.1016\/j.urolonc.2025.02.023_bib0015","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cncr.23567","article-title":"The impact of socioeconomic status on survival after cancer in the United States","volume":"113","author":"Byers","year":"2008","journal-title":"Cancer [Internet]"},{"issue":"703","key":"10.1016\/j.urolonc.2025.02.023_bib0016","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.3399\/bjgp20X713957","article-title":"Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998\u20132017","volume":"71","author":"Clift","year":"2021","journal-title":"British J Gen Pract [Internet]"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:42Z","timestamp":1762363962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1078143925000699"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.023","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do differences in secondary treatment explain mortality impact of prostate cancer screening? \u2013 A randomized screening trial","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}